2.Company name:Microbio (Shanghai) Co.,Ltd.

3.Relationship to the Company (please enter ”head office” or

”subsidiaries”):subsidiary

4.Reciprocal shareholding ratios:NA

5.Cause of occurrence:

(1)New drug name or code: SNS812

(2)Purpose:

A. Treatment for COVID-19 infection

B. Information Website:https://classic.clinicaltrials.gov/ct2/show/

NCT05941793?cond=SNS812&draw=2&rank=1

(3)Planned development stages：Phase II clinical trial/

Phase III clinical trial/NDA

(4)Current development stage:

A. File application/approved/disapproved/Each of clinical trials

(include interim analysis):

SNS812, a broad-spectrum siRNA for treatment of SARS- COV-2 infection,

has been agreed by the US FDA to proceed with the phase 2 clinical

trial.

B. Once disapproved by competent authority or each of clinical trials

(include interim analysis) results less than statistically

significant sense, the risks and the associated measures the

Company may occur: Not applicable

C. After obtaining official approval or the results (include interim

analysis) which are statistically significant, the future strategy:

Not applicable

D. Accumulated investment expenditure incurred: No disclosure of

investment expenditure at the moment in consideration of future

marketing strategies and to protect the interests of the company and

investors.

(5) Upcoming development plan: Phase II/ III clinical trial

A. Scheduled completion date: The actual timeline will depend on the

progress of the trial and the review of the regulatory agency.

B. Estimate responsibilities: SNS812, a broad-spectrum antiviral siRNA

for COVID-19, is developed jointly by Microbio (Shanghai) Co.,Ltd.

and Oneness.

(6)Market:

Based on the data published on July 26, 2023, severe acute respiratory

syndrome coronavirus 2 (SARS-CoV-2) has infected more than 768 million

people worldwide and caused more than 6.95 million deaths. With the

occurrence of vaccine breakthrough and repeated COVID-19 infections

caused by new variants, it is anticipated that the future new variants

will lead to periodic global epidemics.

Pfizer announced in 2023 that its COVID-19 treatment drug (Paxlovid)

has witnessed a significant surge in Q1 sales, soaring from US$1.4

billion in 2022 to US$4.1 billion this year. This far exceeds Wall

Street’s expectation of US$2.7 billion, highlighting the immense

market demand for COVID-19 treatment drugs.

6.Countermeasures:None

7.Any other matters that need to be specified(the information

disclosure also meets the requirements of Article 7, subparagraph 9

of the Securities and Exchange Act Enforcement Rules, which brings

forth a significant impact on shareholders rights or the price of

the securities on public companies.):

(1)According to the Good Review Practice specified in the FDA’s Policy

and Procedures, the review period for the phase 2 clinical trial

protocol is 60 calendar days after submission, which is due by July

30. After confirming with the FDA via email, they informed us today

that the review of this trial cannot be completed at the moment due

to an increased review load for other cases. However, the FDA has

agreed to proceed with this phase 2 trial.

(2)On June 28, 2023, SNS812 has been greenlighted by the Taiwan TFDA

to proceed with the phase II clinical trial. This phase II clinical

trial will enroll participants simultaneously in both the US and

Taiwan to expedite the trial’s progress. In Taiwan, participant

enrollment will begin in September at the main hospital and Yunlin

branch of National Taiwan University Hospital.

(3)According to Guidelines by Taipei Exchange on the Material Information

Announced by Listed and OTC Companies, new drug development companies

shall make public announcement when filing application for clinical

trials to domestic or overseas regulatory authorities, receiving approval

or disapproval, obtaining the statistical date of endpoints in each

clinical trial (including interim analysis), or receiving approval or

disapproval on drug license application.

(4)It takes considerable time and expenses to develop a new drug of which

success can’t be guaranteed. Investors shall bear such investment risk

that warrants careful assessment before making investment decisions.